Tissue-specific inhibition of pyruvate carboxylase reduced plasma glucose concentrations and could be a potential therapeutic approach for nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes [27]. This evidence concerns the gene PC and metabolic dysfunction-associated steatotic liver disease.